BMY

Bristol-Myers Squibb Company
CAPPED RATING

Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and nutritional products. The company operates in two segments namely Pharmaceuticals and Nutritionals.

Bristol-Myers Squibb Company (BMY) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (A-); its weakest is Revisions (D-). The rating has held at C+ for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
B
Factor Score 3.2 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
A-
Factor Score 3.9 / 5.0
Momentum
B
Factor Score 3.2 / 5.0
Revisions
D-
Factor Score 0.8 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 14.1
EV / EBITDA 8.9
Rev Growth YoY 6.9%
Gross Margin 70.5%
Price Return 3M -0.8%
Price Return 12M 35.0%
Catalyst Signal +0.11
Market Cap $129.7B
TTM Revenue $50.0B
Price / Sales 2.6
ROE 44.0%

Historical Factor Score Progression

Held C+ for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 B (3.2) C- (1.9) A- (3.9) B (3.2) D- (0.8) C+ (2.6)
2026-11-09 B (3.2) C- (1.9) A- (3.9) B (3.2) D- (0.8) C+ (2.6)
2026-11-06 B (3.2) C- (1.9) A- (3.9) B- (3.1) C- (2.1) C+ (2.8)
2026-11-05 B (3.2) C- (1.9) A- (3.9) B- (3.0) C- (2.1) C+ (2.8)
2026-11-04 B (3.2) C- (1.9) A- (3.9) B- (3.0) C (2.2) C+ (2.8)
Page 1 of 13
…